Alembic Pharmaceuticals - Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd

"Alembic Pharmaceuticals wholly owned subsidiary Alembic Global Holdings SA has received USFDA Tentative Approval for Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.Treprostinil Injection is indicated for the treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product of United Therapeutics Corp.(United). Treprostinil Injection has an estimated market size of US$ 466.1 million for twelve months ending Dec. 2019 according to United Therapeutics Corporation's 2019 financial results. It is one of the important approvals for Alembic and a new opportunity in Treprostinil Injection for the company."

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.917.6 as compared to the previous close of Rs. 927.4. The total number of shares traded during the day was 11181 in over 956 trades.

The stock hit an intraday high of Rs. 933.65 and intraday low of 908. The net turnover during the day was Rs. 10264420.

Source : Equity Bulls

Keywords